DOCSLIB.ORG

Lothian Drug Trends Relative to Scotland Drug-Related Deaths

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lothian Drug Trends Relative to Scotland Drug-Related Deaths Lothian drug trends relative to Scotland drug-related deaths Scottish Drug Forum Conference 10th October 2018 Dr Paul Cawood Clinical Biochemistry Royal Infirmary of Edinburgh Scotland leads Europe in Drug-Related deaths. Drug-related deaths Scotland trend 1000 934 868 900 2016 had a 23% 800 706 increase over 2015. 700 614 574 584 600 2017 had an 8% 455 500 increase over 2016 382 400 291 300 244 There were regional 200 differences in 2016 with: 100 0 Ayrshire +99% Forth Valley +61% 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 180 Lanarkshire +55% 160 Lothian +28% 160 DRD per million 15-65 yrs (2016) 140 Glasgow/Clyde +16% 120 103 100 100 76 80 71 2017: 60 59 58 Tayside +52% 60 43 40 26 22 22 21 19 16 15 14 Fife +47% 20 10 9 9 8 7 7 6 6 4 4 2 0 Grampian +25% EU UK Italy Glasgow/Clyde +9% Spain Latvia France Turkey Poland Ireland Austria Croatia Finland Estonia Norway belgium Bulgaria Slovakia Slovenia Hungary Portugal Scotland Romania Sweeden Denmark Germany Lithuania Lothian +8% Rep Czech Netherlands Ref: Drug-related deaths Scotland in 2016/2017: National statistics for Scotland Gabapentinoids (opioid boosters) were implicated in 26% of DRDs in 300 Gabapentinoid trend in DRD 2016. 250 200 121 Gabapentin increased by 51% in 2016 71 but decreased in 2017. 150 pregabalin Pregabalin increased by 69% in 2016 42 gabapentin and a further 70% in 2017. 100 36 154 144 50 12 102 67 5 51 24 0 2012 2013 2014 2015 2016 2017 Street benzodiazepines increased from 63 cases in 2015 to 294 in 2016 700 Benzodiazepine trend in DRD 26 and 446 in 2017. 600 99 500 13 Etizolam and Diclazepam were the 75 diclazepam 400 24 main findings in 2016. 21 alprazolam 300 Etizolam and Alprazolam were the delorazepam 300 main findings in 2017 225 etizolam 200 diazepam 43 Correlates with increased DRD in 100 37 205 122 154 Ayrshire, Lanarkshire and Glasgow / 106 85 0 Clyde in 2016, and the East of 2013 2014 2015 2016 2017 Scotland in 2017. 867 Scotland drug-related-deaths 250 200 800 706 650 +23% 2015v16 200 Grampian -2% 2015v16 Highland -18% 2015v16 600 493 426 150 100 2015 400 100 69 68 35 29 21 272 13 12 8 6 3 191 2016 48 50 43 41 50 0 200 63 13 7 DRD Op/meth benzo new benzos 0 0 DRD Op/meth benzo new benzos 250 DRD Op/meth benzo new benzos 200 200 Tayside -2% 2015v16 150 Forth Valley +61% 2015v16 100 100 63 62 49 54 50 36 38 37 8 19 50 31 21 25 8 3 7 0 0 DRD Op/meth benzo new benzos DRD Op/meth benzo new benzos 250 257 GGC +16% 2015v16 200 221 195 150 200 154 Fife +2% 2015v16 138 127 100 44 45 100 50 34 33 29 42 11 3 7 17 0 0 DRD Op/meth benzo new benzos DRD Op/meth benzo new benzos 200 200 Lothian +28% 2015v16 Ayr & Arran +98% 2015v16 128 100 92 85 100 66 100 71 47 43 38 43 38 19 2 12 5 8 0 0 DRD Op/meth benzo new benzos DRD Op/meth benzo new benzos 300 Dumfries & Galloway +55% 2015v16 200 Lanarkshire +55% 2015v16 200 200 113 85 100 Borders -23% 2015v16 100 73 100 46 50 43 11 17 8 7 0 1 0 1 8 4 13 10 8 7 1 3 1 0 0 0 0 DRD Op/meth benzo new benzos DRD Op/meth benzo new benzos DRD Op/meth benzo new benzos 934 1000 867 200 Scotland 2015-2017 250 Highland +10% 706 800 709 200 Grampian +25% 650 100 552 2015 150 35 29 32 21 29 19 600 493 13 12 8 6 3 9 85 426 100 69 68 75 0 347 2016 48 50 58 400 272 43 41 DRD Op/meth benzo new benzos 50 13 191 2017 7 10 200 63 0 DRD Op/meth benzo new benzos 250 0 200 Forth Valley -28% DRD Op/meth benzo new benzos 150 250 200 Tayside +52% 100 50 31 36 21 37 35 25 22 50 8 3 7 13 150 94 83 0 100 63 62 54 65 49 36 38 33 DRD Op/meth benzo new benzos 50 8 19 0 300 280 Glasgow & Clyde +9% DRD Op/meth benzo new benzos 257 242 250 221 195 180 200 164 250 154 138 150 127 200 150 100 Fife +47% 42 100 66 62 45 50 17 44 34 33 29 39 50 11 3 7 11 0 0 DRD Op/meth benzo new benzos DRD Op/meth benzo new benzos 250 250 Lothian +8% 200 Ayrshire & Arran -28% 200 150 137 85 150 128 113 100 61 71 100 92 43 53 43 38 36 38 33 100 66 66 50 5 8 47 50 19 24 0 2 12 DRD Op/meth benzo new benzos 0 DRD Op/meth benzo new benzos 250 250 200 Lanarkshire – 10% 200 200 150 113 Dumfries & Galloway +29% Borders +30% 73 102 85 87 150 100 46 50 51 43 46 100 100 22 22 50 8 11 17 8 7 6 2 50 13 4 0 1 0 1 13 10 8 7 11 1 3 7 0 1 2 0 0 0 DRD Op/meth benzo new benzos DRD Op/meth benzo new benzos DRD Op/meth benzo new benzos 1000 934 Scotland DRD drug trends 2012-2017 900 867 800 706 700 613 600 581 2012 552 2013 500 473 470 2014 439 426 2015 2016 400 362 345 347 2017 300 272 237 221 196 205 200 176 160 154 123 100 63 31 36 0 DRD Heroin Methadone Cocaine benzo diazepam Benzo other What is killing drug users in Scotland? • Opiates/methadone are implicated in most DRD, but poly drug use is likely to be a major contributing factor. • Heroin implicated in 55% of DRD in 2016 falling to 50% in 2017. • Methadone implicated in 42% of DRD in 2016 increasing to 47% in 2017. • Gabapentinoids implicated in 26% of DRD in 2016 increasing to 28% in 2017. Switch from gabapentin to more potent pregabalin in 2017. • Benzodiazepines implicated in 59% of DRD in 2017 with large increase in more potent street benzodiazepines but with regional variations. • Etizolam and Xanax implicated in 43% of DRD in 2017. • Trend of increase in cocaine: implicated in 14.2% DRD in 2016 and 18.9% in 2017. Benefits of specific drug analysis by tandem MS v immunoassay • Cost effective: £12 per sample 24 drugs analysed to confirmation standards on every sample: • Opiates: morphine, codeine, 6MAM, DHC, Oxycodone • Methadone, buprenorphine, tramadol • Amphetamine, MDMA, Methamphetamine • Cocaine + benzoyl ecgonine • Gabapentin + Pregabalin • Benzos: Diazepam Nordiazepam temazepam oxazepam nitrazepam • Street benzo: etizolam, diclazepam, delorazepam, alprazolam. • No false positive and more sensitive than immunoassay. Liquid Chromatography - Tandem Mass Spectrometer Detector TANDEM MS Detector Lothian have an established, cost effective Tandem MS method for drugs of abuse • Lothian service covers both urine and oral fluid. • 50µL sample 6 min. per sample • ISO 15189 accredited proven method • >40,000 urine; >40,000 oral fluid to date • Electronic ordering and reporting • Cannabis only available in urine by immunoassay screening Chromatogram of 24 drugs Diclazepam Diazepam Oral fluid chromatogram analysed on Delorazepam Waters Xevo Tandem MS in 5.2 minutes Temazepam Nordiazepam Etizolam Alprazolam Urine also includes EDDP, Methadone Norbuprenorphine and Oxazepam 7-amino-clonazepam Nitrazepam Buprenorphine Cocaine Tramadol Benzoyl ecgonine MDMA Methamphetamine Amphetamine 6 mono-acetyl morphine Oxycodone Pregabalin Gabapentin Codeine Dihydrocodeine Morphine Drug identification: 1) Retention times match Internal Standard 2) Peaks are same shape. Calibration curve 3) Ratio of quantifying : qualifying match calibrators. Quantifying ion Calibrators 5µg/L 10µg/L 30µg/L Quality 100µg/L Control 300µg/L Qualifying ion 10µg/L 1000µg/L 20µg/L 50µg/L 100µg/L 300µg/L 400µg/L Internal Standard Source of oral fluid drug thresholds Threshold oral Threshold oral Drug Threshold oral fluid Threshold oral fluid fluid fluid EWDTS DRiving Under Influence of Drugs European Workplace Drug Testing DRUID EWDTS screen confirmation RIE Morphine 20 40 40 20 Codeine 20 40 40 20 6MAM 20 4 4 10 DHC 20 40 40 20 AMP 50 40 30 30 Met AMP 50 40 30 30 MDMA 50 40 30 30 Cocaine 10 30 8 10 BEC 10 30 8 10 Methadone 20 50 20 20 EDDP 50 20 NA Diazepam 5 10 10 1 Nordiazepam 1 10 10 1 Temazepam 1 10 10 5 Oxazepam 1 10 10 5 Nitrazepam 1 10 10 5 Clonazepam 1 10 10 NA Gabapentin/Pregab 40 Tramadol 40 Buprenorphine 5 5 1 Norbuprenorphine 5 5 NA Drug thresholds and duration of detectability Drug Threshold Threshold Duration of detectability urine µg/L Oral fl µg/L Amphetamine MDMA 300 30 48 hrs urine Methamphetamine 24 hrs oral fluid Diazepam Nordiazepam 5 1 long-acting 7+ day urine Other Benzodiazepines 5-20 1-5 <7 days Oral fluid Cannabinoids 50 N/A 2-28 days urine – varies with usage Cocaine metabolite 300 10 48 -72 hrs urine Cocaine N/A 10 1-5 days oral fluid Methadone 300 20 7 days urine EDDP 100 N/A <7 days Oral fluid Opiates 50 20 48 hrs urine 6-MAM 50 10 1-5 days oral fluid Buprenorphine N/A 1 <12-48 hrs Oral fluid Norbuprenorphine 10 N/A 4-6 days urine Gabapentinoids 300 40 48 hrs urine Tramadol 300 40 <48 hrs Oral fluid Heroin (Diacetyl Morphine + Acetyl Codeine) - metabolised too quickly to detect in urine 6-MonoAcetyl Morphine 327.4 Conjugates Morphine 285.3 Codeine 299.4 Hydrocodone 299.4 Dihydrocodeine 301.4 Conjugates Benzodiazepine metabolism Chlordiazepoxide (librium) T½ 6-28 h Diazepam (valium) T½ 20-70 h Nordiazepam T½ 39-96h Nitrazepam T½ 20-30 h Oxazepam* T½ 5-15 h Clonazepam T½ 18-50 h Temazepam* T½ 8-20 h Flunitrazepam T½ 10-40 h Conjugation 7-Amino metabolites Urinary Excretion Active drug Drugs implicated in Drug-related deaths in Lothian 2015-2017 160 Lothian DRD - drug trends 137 • DRD continue to increase 140 128 • Heroin peaked in 2016 • Methadone increase 120 • Cocaine increase 100 • Benzos increase 100 • Diazepam increase 2015 • Street benzos increase 80 2016 66 63 62 2017 60 54 51 49 43 42 38 40 35 37 24 19 20 15 17 12 8 2 0 DRD Heroin Methadone cocaine Benzo diazepam other benzo 60 Heroin: 48.9% - 32.4% = 34% drop 50 Cocaine: 15.7%-33.3% = 112% increase 40 30 6-MAM Cocaine 20 10 0 60 50 40 30 Cocaine only 6MAM+Cocaine 20 6MAM only 10 0 10 20 30 40 50 60 70 80 90 0 Jan-16 Feb-16 positive fluid % in oral and buprenorphine Methadone Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 methadone Buprenorphine 10 15 20 25 30 Gabapentinoid trend analysis in Lothian analysis Jan2016 Septrend 2018 Gabapentinoid to survey among substance misusers.
Load more

Recommended publications
  • Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2016
    Table 6.12: Deaths from poisoning, by sex and cause, Scotland, 2016 ICD code(s), cause of death and substance(s) 1 Both Males Females ALL DEATHS FROM POISONING 2 1130 766 364 ACCIDENTS 850 607 243 X40 - X49 Accidental poisoning by and exposure to … X40 - Nonopioid analgesics, antipyretics and antirheumatics Paracetamol 2 1 1 Paracetamol, Cocaine, Amphetamine || 1 0 1 X41 - Antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified Alprazolam, MDMA, Cocaine || Cannabis, Alcohol 1 1 0 Alprazolam, Methadone || Pregabalin, Tramadol, Gabapentin, Cannabis 1 1 0 Alprazolam, Morphine, Heroin, Dihydrocodeine, Buprenorphine || Alcohol 1 1 0 Alprazolam, Oxycodone, Alcohol || Paracetamol 1 0 1 Amitriptyline, Cocaine, Etizolam || Paracetamol, Codeine, Hydrocodone, Alcohol 1 1 0 Amitriptyline, Dihydrocodeine || Diazepam, Paracetamol, Verapamil, Alcohol 1 1 0 Amitriptyline, Fluoxetine, Alcohol 1 0 1 Amitriptyline, Methadone, Diazepam || 1 1 0 Amitriptyline, Methadone, Morphine, Etizolam || Gabapentin, Cannabis, Alcohol 1 1 0 Amitriptyline, Venlafaxine 1 0 1 Amphetamine 1 1 0 Amphetamine || 1 1 0 Amphetamine || Alcohol 1 1 0 Amphetamine || Chlorpromazine 1 1 0 Amphetamine || Fluoxetine 1 1 0 Amphetamine, Dihydrocodeine, Alcohol || Procyclidine, Tramadol, Duloxetine, Haloperidol 1 0 1 Amphetamine, MDMA || Diclazepam, Cannabis, Alcohol 1 1 0 Amphetamine, Methadone || 1 1 0 Amphetamine, Oxycodone, Gabapentin, Zopiclone, Diazepam || Paracetamol, Alcohol 1 0 1 Amphetamine, Tramadol || Mirtazapine, Alcohol 1 1 0 Benzodiazepine
    [Show full text]
  • Benzodiazepine Group ELISA Kit
    Benzodiazepine Group ELISA Kit Benzodiazepine Background Since their introduction in the 1960s, benzodiazepines have been widely prescribed for the treatment of anxiety, insomnia, muscle spasms, alcohol withdrawal, and seizure-prevention as they are depressants of the central nervous system. Despite the fact that they are highly effective for their intended use, benzodiazepines are prescribed with caution as they can be highly addictive. In fact, researchers at NIDA (National Institute on Drug Abuse) have shown that addiction for benzodiazepines is similar to that of opioids, cannabinoids, and GHB. Common street names of benzodiazepines include “Benzos” and “Downers”. The five most encountered benzodiazepines on the illicit market are alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium), and temazepam (Restori). The method of abuse is typically oral or snorted in crushed form. The DEA notes a particularly high rate of abuse among heroin and cocaine abusers. Designer benzodiazepines are currently offered in online shops selling “research chemicals”, providing drug abusers an alternative to prescription-only benzodiazepines. Data defining pharmacokinetic parameters, drug metabolisms, and detectability in biological fluids is limited. This lack of information presents a challenge to forensic laboratories. Changes in national narcotics laws in many countries led to the control of (phenazepam and etizolam), which were marketed by pharmaceutical companies in some countries. With the control of phenazepam and etizolam, clandestine laboratories have begun researching and manufacturing alternative benzodiazepines as legal substitutes. Delorazepam, diclazepam, pyrazolam, and flubromazepam have emerged as compounds in this class of drugs. References Drug Enforcement Administration, Office of Diversion Control. “Benzodiazepines.” http://www.deadiversion.usdoj.gov/drugs_concern/benzo_1.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe
    EMBARGO — 7 JUNE 7. 6. 2018 UPDATED 11:30 Central European Time/CET (10:30 Western European Time/WET/Lisbon) Proof - 28 May 2018 not for circulation PERSPECTIVES ON DRUGS The misuse of benzodiazepines among high-risk opioid users in Europe Benzodiazepines are a widely prescribed I Introduction group of medicines with a range of clinical uses that include treating Benzodiazepines have a range of clinical uses and are among the most commonly prescribed medicines globally. anxiety, insomnia and managing alcohol They are useful in the short-term treatment of anxiety and withdrawal. This group of medicines is insomnia, and in managing alcohol withdrawal (Medicines often misused by high-risk opioid users, and Healthcare Products Regulatory Agency, 2015). Like all medicines, benzodiazepines can produce side effects. They and this is associated with considerable may also be misused, which we define as use without a morbidity and mortality. This paper prescription from a medical practitioner or, if prescribed, when describes the impact of benzodiazepines they are used outside accepted medical practice or guidelines. misuse on the health and treatment of While the misuse of benzodiazepines has been identified high-risk opioid users. as a concern for large groups in the general population, for example, among elderly people and women, this analysis focuses specifically on misuse among high-risk opioid users (1), a group of people among whom these medicines have been linked with severe treatment challenges and implicated in considerable numbers of drug-related deaths. It is important to stress that much benzodiazepine prescribing to high-risk drug users is done with legitimate therapeutic aims in mind.
    [Show full text]
  • Glucuronidase-Mediated Reduction of Oxazepam and Temazepam
    1 Reduction of temazepam to diazepam and lorazepam to delorazepam during enzymatic 2 hydrolysis 3 4 Shanlin Fu • Anna Molnar • Peter Bowron • John Lewis • Hongjie Wang 5 6 7 8 9 10 S. Fu () · A. Molnar · J. Lewis 11 Centre for Forensic Science, University of Technology, Sydney (UTS), Broadway, NSW, 12 Australia 2007 13 e-mail: [email protected] 14 15 P. Bowron 16 Toxicology Unit, Pacific Laboratory Medicine Services, Macquarie Hospital, North Ryde, 17 NSW, Australia 2113 18 19 H. Wang 20 National Measurement Institute, 1 Suakin Street, Pymble, NSW, Australia 2073 21 22 Page 1 of 29 1 Abstract 2 3 It has been previously reported that treatment of urinary oxazepam by commercial β- 4 glucuronidase enzyme preparations, from Escherichia coli, Helix pomatia, and Patella 5 vulgata, results in production of nordiazepam (desmethyldiazepam) artefact. In this study, we 6 report that this unusual reductive transformation also occurs in other benzodiazepines with a 7 hydroxyl group at the C3 position such as temazepam and lorazepam. As determined by LC- 8 MS analysis, all three enzyme preparations were found capable of converting urinary 9 temazepam into diazepam following enzymatic incubation and subsequent liquid-liquid 10 extraction procedures. For example, when H. pomatia enzymes were used with incubation 11 conditions of 18 h and 50 °C, the percentage conversion, although small, was significant – 12 approximately 1 % (0.59% - 1.54%) in both patient and spiked blank urines. Similarly, using 13 H. pomatia enzyme under these incubation conditions, a reductive transformation of urinary 14 lorazepam into delorazepam (chlordesmethyldiazepam) occurred. These findings have both 15 clinical and forensic implications.
    [Show full text]
  • Table 6.12: Deaths from Poisoning, by Sex and Cause, Scotland, 2015
    Table 6.12: Deaths from poisoning, by sex and cause, Scotland, 2015 ICD code(s), cause of death and substance(s) 1 Both Males Females ALL DEATHS FROM POISONING 2 941 632 309 ACCIDENTS 662 471 191 X40 - X49 Accidental poisoning by and exposure to … X40 - Nonopioid analgesics, antipyretics and antirheumatics Paracetamol 2 0 2 Paracetamol, Codeine || Diazepam, Amitriptyline, Mirtazapine, Dihydrocodeine, Cannabis, Alcohol 1 0 1 Paracetamol, Dihydrocodeine, Tramadol || 1 1 0 X41 - Antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified Amitriptyline || Tramadol, Diazepam 1 0 1 Amitriptyline || Venlafaxine, Dihydrocodeine 1 0 1 Amitriptyline, Alcohol 1 0 1 Amitriptyline, Alcohol || Fluoxetine 1 0 1 Amitriptyline, Clomipramine, Gabapentin, Tramadol, Methadone 1 0 1 Amitriptyline, Gabapentin, Fluoxetine || Paracetamol, Diazepam, Tramadol, Cannabis 1 0 1 Amitriptyline, Oxycodone || Pregabalin 1 0 1 Amitriptyline, Zopiclone, Oxycodone, Venlafaxine, Pregabalin 1 0 1 Amphetamine || Diazepam 1 0 1 Amphetamine || Diazepam, Cannabis 1 0 1 Amphetamine || Diazepam, Paracetamol, Alcohol 1 1 0 Amphetamine || Dihydrocodeine, Alcohol 1 0 1 Amphetamine, Citalopram || Diazepam, Cannabis, Alcohol 1 0 1 Citalopram, Alcohol 2 1 1 Citalopram, Cyclizine || Temazepam 1 1 0 Diazepam, Alcohol || 2 2 0 Diazepam, Dihydrocodeine || Pregabalin, Venlafaxine, Quetiapine 1 1 0 Diazepam, Dihydrocodeine, Alcohol || 1 1 0 Diazepam, Methadone, Mirtazapine || 1 0 1 Dothiepin 1 0 1 Ecstasy, Cocaine, Alcohol 1 1 0 Ethylphenidate, Diazepam,
    [Show full text]
  • Flualprazolam Article Originally Appeared in TOXTALK®, Volume 43, Issue 4
    Donna Papsun¹, MS, D-ABFT-FT, Craig Triebold², F-ABC, D-ABFT-FT Emerging Drug: ¹NMS Labs, Horsham, PA; ²Sacramento County District Attorney Laboratory of Forensic Services, Sacramento, CA Flualprazolam Article originally appeared in TOXTALK®, Volume 43, Issue 4 In recent years, there has been an increase of misuse related to designer benzodiazepines (DBZD), a subcategory of novel psychoactive substances (NPS). Benzodiazepines are commonly prescribed for their anxiolytic, muscle relaxant, sedative- hypnotic, and anticonvulsant properties, but due to their widespread availability and relatively low acute toxicity, there is a high potential for misuse and dependence. Therefore, in the era of analogs of commonly used substances emerging on the drug market as suitable alternatives, it is not unexpected that designer variants of benzodiazepines have become available and in demand. Compounds of this class may have either been repurposed from pharmaceutical research, chemically modified from prescribed benzodiazepines, or obtained from diversion of pharmaceuticals available in other countries. Flualprazolam, a fluorinated analog of alprazolam, is an emerging designer benzodiazepine with increasing prevalence, which is an example of a modification to a prescribed benzodiazepine. It was first patented in the 1970s but never marketed, so it has been repurposed for recreational abuse from pharmaceutical research as well (1). Its chemical characteristics and structure are listed in Figure 1. Flualprazolam is a high potency triazolo-benzodiazepine with sedative effects similar to other benzodiazepines (2). It is marketed by internet companies for “research purposes” as an alternative to alprazolam and discussions on online forums suggest that flualprazolam lasts longer and is stronger than alprazolam, its non-fluorinated counterpart (3).
    [Show full text]
  • Summary of Product Characteristics 1
    SUMMARY OF PRODUCT CHARACTERISTICS 1 DENOMINATION OF THE MEDICINAL PRODUCT DELORAZEPAM ABC 1 mg/ml Oral drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION DELORAZEPAM ABC 1 mg/ml Oral drops, solution 1 ml of solution contains: Active principle: delorazepam 1 mg For the excipients, refer to 6.1. 3. Pharmaceutical form Oral drops, solution. 4. CLINIC INFORMATION 4.1 Therapeutical indications Dysphoria, Insomnia. The benzodiazepines are indicated only when the disorder is serious, disabling or the subject is submitted to serious uneasiness. 4.2 Posology and administration modality Anxiety trouble In general medicine -oral drops, solution: 13-26 drops, for 2-3 times a day. In neuro-psychiatry - oral drops, solution: 26-50 drops, for 2-3 times a day. The anxiety trouble treatment should be in terms of time as short as possible. The patient should be regularly re-valued and the necessity of a continued treatment should be attentively evaluated, particularly when the patient is without symptoms. The total treatment duration should not exceed, generally, 8-12 weeks, including a period of gradual suspension. In specific cases, the extension of treatment beyond the maximum period may be necessary; in such case, this should not occur without the patient condition re-evaluation. Insomnia -oral drops, solution: 13-26-52 drops, in the evening before going to sleep. The insomnia treatment, in terms of time, should be as brief as possible. The treatment duration, generally, varies from a few day to two weeks up to a maximum of four weeks, including a period of gradual suspension. In specific cases it may be necessary the extension beyond the period of maximum treatment; in such case, this should not happen without a previous re-evaluation, by the physician, of the patient conditions.
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • Endogenous Benzodiazepine-Like Compounds and Diazepam Binding Inhibitor in Serum of Patients Gut: First Published As 10.1136/Gut.42.6.861 on 1 June 1998
    Gut 1998;42:861–867 861 Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of patients Gut: first published as 10.1136/gut.42.6.861 on 1 June 1998. Downloaded from with liver cirrhosis with and without overt encephalopathy R Avallone, M L Zeneroli, I Venturini, L Corsi, P Schreier, M Kleinschnitz, C Ferrarese, F Farina, C Baraldi, N Pecora, M Frigo, M Baraldi Abstract The involvement of this receptor system in Background/Aim—Despite some contro- overt hepatic encephalopathy (OHE), discov- versy, it has been suggested that endog- ered in the 1980s during studies on GABAA enous benzodiazepine plays a role in the receptors in the brain of animals with OHE, pathogenesis of hepatic encephalopathy. was considered likely when specific benzodi- The aim of the present study was to evalu- azepine receptor antagonists were shown to ate the concentrations of endogenous ben- revert the symptoms of encephalopathy in ani- zodiazepines and the peptide, diazepam mal models4 and in patients.56 Later, the binding inhibitor, in the blood of patients observation of an increased presence of endog- with liver cirrhosis with and without overt enous benzodiazepine receptor ligands (BZDs) encephalopathy, and to compare these in animals and patients with OHE7–13 suggested levels with those of consumers of com- that this phenomenon may contribute to the mercial benzodiazepines. enhancement of GABAergic neurotrans- 14 Subjects—Normal subjects (90), benzodi- mission. We cannot exclude, however, the azepine consumers (14), and cirrhotic possibility that compounds such as 1315 16 patients (113) were studied. ammonia or neurosteroids contribute to Methods—Endogenous benzodiazepines the above mentioned increased functional were measured by the radioligand binding activity of the GABAA receptor system.
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]